Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a pivotal development in its quest to address multiple sclerosis (MS) through its subsidiary, Huge Biopharma Australia Pty Ltd. The company has entered into an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS. This formulation is intended for use in Quantum BioPharma's upcoming Phase 2 clinical trial, which aims to evaluate the therapy's potential to restore mobility in individuals suffering from MS.

Lucid-MS represents a groundbreaking approach to treating MS, being a patented, first-in-class, non-immunomodulatory neuroprotective compound. It has shown promise in preclinical studies over the past decade, demonstrating the ability to prevent demyelination—the process underlying MS and other neurodegenerative diseases. Notably, these studies have observed animals regaining their ability to walk, offering hope for similar outcomes in humans.

The agreement with the CDMO is a critical milestone for Quantum BioPharma, as it moves closer to filing an Investigational New Drug (IND) application with the FDA for Lucid-21-302 in MS. This development not only underscores the company's commitment to addressing unmet medical needs in neurodegenerative diseases but also highlights the potential of Lucid-MS to revolutionize MS treatment.

For more information on Quantum BioPharma's innovative approach to MS treatment and its recent developments, visit https://ibn.fm/y8RRY. Additionally, updates and news related to QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.

This announcement is significant for the biopharmaceutical industry, patients with MS, and investors alike. It represents a forward leap in the development of treatments that could potentially halt or reverse the progression of MS, a condition that affects millions worldwide. The implications of a successful Phase 2 trial and subsequent FDA approval could be profound, offering new hope to those affected by this debilitating disease.